Objective: Preterm neonates undergo numerous painful procedures in the neonatal intensive care unit (NICU). Sucrose, with and without pacifiers, is effective and safe for relieving pain from single painful events. However, repeated use of sucrose for multiple painful procedures has not been adequately evaluated. The study objectives were to: 1) determine the efficacy and safety of consistent management of repeated procedural pain with sucrose; and 2) explore the impact of consistent pain management on clinical outcomes and neurobiological risk status.
O ver the past decade, survival rates for preterm neonates have increased markedly. 1 However, this improvement has been accompanied by a corresponding increase in the incidence and frequency of painful procedures, including surgery. [2] [3] [4] [5] [6] Although the management of neonatal pain from major single procedures (eg, postoperative pain) has improved significantly, 7 pain management for multiple and repetitive diagnostic and therapeutic procedures (eg, heel lances, suctioning) has not kept pace. Sabrine and Sinha, 6 in a survey of 86 neonatal intensive care units (NICUs), reported that analgesia was used less than 10% of the time for invasive procedures including intravenous cannulations, venipunctures, and lumbar punctures and only 16% of the time for highly invasive procedures such as chest drain insertion. Similarly, Johnston et al, 8 in a study of 14 NICUs, reported that there was good analgesic coverage for postoperative pain but not for procedural pain and particularly pain from repeated procedures.
Pain may have profound consequences for preterm neonates during a critical time of brain development. [9] [10] [11] Data derived from animal models suggests that repeated painful stimuli may result in structural and functional reorganization of the nervous system and alteration in future pain responses. [11] [12] [13] Early pain experiences during this critical period in development are thought to have immediate and long-term consequences that could influence physiological, behavioral, and developmental outcomes. 10 The underlying cellular and molecular mechanisms for long-term effects are largely speculative but may include: 1) neuronal excitotoxicity (mediated via activation of NMDA or other excitatory receptors); or 2) enhanced apoptosis due to multiple metabolic stresses or lack of social stimulation. 14 The optimal approach for managing procedural pain in infants in the NICU remains elusive. The research emphasis has been on evaluating the safety and effectiveness of behavioral strategies for managing pain from single painful events. Sucrose has been the most frequently studied intervention for the relief of procedural pain from heel lance and venipuncture in the neonate. Sucrose has been shown to be effective in reducing physiologic (eg, heart rate) and behavioral (eg, cry, facial action) pain indicators and composite pain scores in neonates undergoing heel stick or venipunture. 15 The effects of sucrose are thought to be mediated by endogenous opioid pathways activated by sweet taste that endure after the painful stimulus (orogustatory effect). 16, 17 Supporting this potential mechanism of action is evidence that: 1) the effect of sucrose was reversed with naloxone or naltrexone in infant rats 18, 19 ; and 2) sucrose was not effective in infants born to women who were administered methadone during their pregnancy. 18 The efficacy of the coadministration of nonnutritive sucking (NNS; pacifiers) and sucrose has also been studied for pain from heel lance 18, 20 and immunization 21 in term infants. In all cases, the combination of NNS and sucrose was more efficacious than either was alone. Blass and Ciaramitaro 18 suggest that the coadministration of sucrose with NNS (pacifiers) may be additive or interactive but most likely depends on normal functioning of central opioid-dependent (sucrose) and nonopioid-dependent (NNS) mechanisms. When Stevens et al 22 examined the combined efficacy of sucrose and NNS for relieving pain from a single heel lance in preterm infants, significant differences in pain were found between infants receiving the pacifier with water and pacifier with sucrose compared with the control intervention.
Although researchers report that sucrose is safe and has no adverse effects for single painful events, 23 the safety of repeated administration of sucrose for large numbers of frequently performed painful procedures on neonates in the NICU has not been adequately determined. In a 30-year-old study, Willis et al 24 reported that frequent small volumes of a 20% sucrose and calcium lactate solution given by nasogastric tube were associated with an increased incidence of necrotizing enterocolitis (NEC) in very low birth weight infants. More recently, Johnston et al 25 evaluated the repeated use of sucrose for painful procedures during the first 7 days of life. Although there were no significant effects on any outcomes between groups, there was an age-related effect with infants ,31 weeks gestational age (GA) at increased risk for some neurologic and physiologic outcomes. Although there is substantial evidence to support the efficacy and safety of behavioral interventions for pain from single procedures, the data supporting consistent implementation of pain-relieving strategies for repeated painful procedures is sparse. Before we employ sucrose liberally for repeated painful procedures, we need to know more about its efficacy and safety and how this intervention influences clinical outcomes during the neonatal period.
The specific aims for this study were: 1) to determine if consistent management of procedural pain with sucrose from repeated painful procedures in preterm newborns in the NICU is effective and safe throughout the neonatal period; and 2) to explore the impact of repeated painful procedures on clinical outcomes and neurobiological risk status. We hypothesized that sucrose plus NNS and water plus NNS would be more effective when administered consistently for procedural pain compared with standard care. We also hypothesized that there would be no difference in adverse events or neurobiological risk status between groups.
MATERIALS AND METHODS

Study Participants
A prospective randomized control design with repeated measures was used. The sample was recruited from 1 tertiary level NICU in Canada. All neonates who were .26 weeks GA and ,30 weeks GA based on early ultrasound, appropriate for GA using the criteria by Usher and McLean 26 and ,72 hours postnatal age (PNA), were eligible for inclusion in the study. Infants who had major congenital anomalies requiring correction during the first week of life or who had undergone major stressful procedures during the first 72 hours PNA were ineligible to participate. A convenience sampling strategy was used, including all infants who met the inclusion criteria and for whom consent was received. The Research Ethics Board at the university-affiliated pediatric hospital approved this study.
Intervention
After the study was explained and parental consent was obtained by the research nurse, baseline data were collected and eligible infants were randomized, using central randomization and allocation concealment, to one of the groups listed below.
Standard Care Group
Infants were positioned on their back or in a side-lying position and contained in a Snuggle-Up device (Children's Medical Ventures, So. Weymouth, MA) prior to and during each painful procedure undertaken in the NICU during the first 28 days of life.
Water Plus Pacifier Group
Infants were positioned and contained in the same way as infants in the standard care group. Infants also received 0.1 mL of sterile water via oral syringe, immediately followed by the insertion of a Wee Thumbie pacifier (Children's Medical Ventures) 2 minutes prior to each painful procedure undertaken in the NICU during the first 28 days of life.
Sucrose Plus Pacifier Group
Infants were positioned and contained in the same way as infants in the standard care group. Infants also received 0.1 mL of 24% sucrose via oral syringe, immediately followed by the insertion of a pacifier 2 minutes prior to each painful procedure undertaken in the NICU during the first 28 days of life.
Standard care and treatment interventions were initiated by the nurses caring for the infant prior to all painful procedures from the time of study entry until 28 days of life or discharge from the NICU.
Group assignment sequence was determined a priori from a computer-generated table of random numbers and recorded on a master sheet that was available only to the neonatal pharmacist. Only the pacifier groups were blinded due to ability to visualize the pacifier. A study package was delivered to the infant's bedside by the research pharmacist. The sterile water and 24% sucrose solutions were kept in dark glass opaque bottles, and the solutions were identical in color and consistency. The solution bottle was replaced weekly.
Outcomes and Measures
The primary outcomes were efficacy (pain response) and safety of the treatment interventions. Pain response was assessed using the Premature Infant Pain Profile (PIPP) 27 during a heel lance procedure at 4 data collection points at day 7 (session 1), day 14 (session 2), day 21 (session 3) and day 28 (session 4) of life. The PIPP is a 7-indicator, 4-point composite pain scale consisting of 3 behavioral (facial actions: brow bulge, eye squeeze, and nasolabial furrow), 2 physiologic (heart rate, oxygen saturation), and 2 contextual (gestational age, behavioral state) indicators of infant pain. The PIPP has demonstrated moderate internal consistency (0.59-0.76 itemtotal correlations), high interrater (alpha = 0.95-0.97) and intrarater reliability (alpha = 0.89-0.91), 27, 28 and construct validity. [29] [30] [31] Safety was also assessed at each session by recording the incidence of immediate and long-term adverse events using criteria articulated by Gibbins et al. 23 Immediate adverse events were defined by neonatal experts as: 1) heart rate .240 or ,100 beats/min; 2) oxygen saturation ,85%; 3) apnea .15 seconds; and 4) choking. Long-term adverse events were defined as: 1) hyperglycemia .10.0 mmol; 2) oral infection; 3) NEC; 4) intraventricular hemorrhage (IVH) grades 3 or 4; and 5) death.
The secondary outcomes, collected at day 28 of life, explored the impact of repeated painful procedures on neurobiological risk status and clinical outcomes. The Neurobiologic Risk Score (NBRS) is a 7-item scale scored at NICU discharge to assess the degree of hypoxemia, ischemia, metabolic aberration, and brain injury occurring during the course of the infant's hospitalization. The NBRS has demonstrated significant correlation with the Bayley Mental Index (r = 0.43) and psychomotor development (r = 0.51) and neurologic examination score (r = 0.65) for up to 24 months corrected age. 32 Clinical outcomes measured were days on ventilator, days on continuous positive airway pressure (CPAP), days until no apnea, bradycardia, and/or desaturation, days until birth weight was regained, days to full enteral feeds, days until full breast/bottle feeds, and days until discharge home.
Severity of illness was assessed using the Neonatal Therapeutic Intervention Scoring System (NTISS) 33 and the Score for Neonatal Acute Physiology: Perinatal Extension (SNAP: PE).
34-36
Data Collection Procedures
Prior to randomization, each infant's baseline birth weight, GA at birth, 5 minute Apgar score, severity of illness scores (NTISS and SNAP:PE), and sex were obtained from patient medical records. Information was also collected on the total number of painful procedures performed on the infants over the first 28 days of life. Painful procedures were defined as invasive, tissue-damaging cutaneous procedures including, but not limited to, heel lance, intravenous or arterial line insertion, lumbar puncture, and tape removal. Behavioral and physiological data were collected during a routinely scheduled heel lance procedure using videotaping and a computerized data collection system. The heel lance was performed by the research nurse at regularly scheduled blood collection times. Standardized phases of the heel lance procedure included; baseline (1 minute), warming (2 minutes), heel stick (15 seconds), heel squeeze (30-second blocks of time), and return to baseline (5 minutes). The heel warming device (Omni Disposable Infant Heel Warmer; Omni Therm Inc., St. Louis, MO) and lancets (Microtainer Safety Flow Lancet, BecktonDickinson, Rutherford, NJ) were standardized. The number of heel sticks and squeezes for each heel lance differed; therefore, these phases varied in number and duration across infants.
Facial action pain indicators were videotaped using an 8-mm camcorder (Sharp VLH420 with video screen and real time counter, Mississauga, Ontario, Canada) through all phases of the heel lance procedure. Physiologic indicators were recorded using a pulse oximeter (Nellcor Pulse Oximeter, Model N-3000; Hayward, CA) and the SATMASTER data collection system (EMG, Los Angeles, CA). Data were sampled at 100 Hz and recorded second to second. Signals, digitalized in the pulse oximeter, were transferred into a personal computer (PC). Simultaneous verbal and electronic event markers signaled the phases of the heel lance procedure on physiologic (electronic) and videotaped (verbal) data. The facial action and physiologic indicators used to calculate the PIPP scores were completed by a trained coder who was blind to the study group assignment (for pacifier groups). All data were verified and double entered into an Access database. Logic checks were performed and indicated an error rate in data entry of ,1%.
Data Analysis
Data were described using means standard deviation for continuous variables and frequencies (percentages) for categorical data. One-way analysis of variance (ANOVA) was used to describe the groups prior to randomization and the number of painful procedures by study session.
Efficacy and Safety
A likelihood-based method where all available cases were incorporated into a repeated measures analysis of variance (RMANOVA) was employed in the analysis of PIPP scores. An autoregressive of order 1 (AR1) correlation structure was assumed for the within-patient factor. This structure accounts for the strong correlation for measurements that are closer to each other and weaker correlations among measurements that are further apart from each other. Chi-square analyses were employed to compare the incidence of immediate and long-term adverse events. A significance level of 0.05 was used for the primary outcome and 0.01 for the secondary outcomes, as they were exploratory in nature.
Secondary Outcomes
Neonatal clinical outcomes and neurobiological risk scores were analyzed using one-way ANOVA. Data were analyzed using the SAS statistical software, version 8.2 (SAS Institute Inc., Cary, NC).
RESULTS
Ninety-four eligible patients were approached to participate in this study. Twenty-six (28.8%) refused to participate. Reasons for refusals included parents who: provided no reason (10), were not interested (7), were too stressed (7), were q 2005 Lippincott Williams & Wilkins concerned about the study group allocation (2), or had limited understanding of English that was not evident when considering eligibility. Two infants dropped out of the study prior to any data collection. There were no differences found between infants whose parents declined to participate or dropped out of the study (n = 28) and those who participated (n = 66). There were no significant differences in any infant demographic characteristics or severity of illness between groups ( Table 1 ). The number of painful procedures across study periods also did not differ between groups (Table 2 ).
Efficacy and Safety
When PIPP scores were compared between groups over time, there was no intervention by time interaction [F(6,95) = 0.76, P = 0.60]. However, a significant main effect of group [F(2,60) = 3.53, P = 0.03] was found. Post hoc analysis indicated that significant differences occurred between the sucrose plus pacifier group and the standard care group [t (60) = 22.54, P = 0.01]. Differences between the water plus pacifier group and the standard care group approached significance [t (60) = 21.99, P = 0.051]. Mean PIPP scores were generally higher in the standard care group over time (Fig. 1) . There was no significant main effect of time [F(3,95) = 0.44, P = 0.72].
There were no statistically significant differences between groups on the number of immediate adverse events that included heart rate ,100 and .240 bpm, oxygen desaturation ,85%, apnea .15 seconds, and choking at each follow-up session (P . 0.05). Similarly, there were no significant differences between groups for the number of longterm adverse events consisting of hyperglycemia .10.0 mmol, oral infection, NEC IVH grades 3 or 4, and death (P . 0.05).
Secondary Outcomes
When clinical outcomes (ie, days on ventilator, days on CPAP, days until no apnea, bradycardia, and/or desaturation, days until birth weight was regained, days to full enteral feeds, days until full breast/bottle feeds, and days until discharge home) were measured at session 4 (28 days), no statistically significant differences were found between groups. Neurobiologic risk scores using the NBRS were also similar across groups (Table 3) .
DISCUSSION
The results of this study support our hypotheses and provide preliminary evidence of the efficacy and safety of consistent use of pacifiers in combination with sucrose in reducing procedural pain in preterm infants. That is, significant differences existed in the sucrose with pacifier intervention groups compared with the standard care group. Gibbins et al 23 reported lower PIPP scores in preterm and term infants who received a single dose of sucrose with pacifier and water with pacifier compared with sucrose alone just prior to a heel lance. Blass and Hoffmeyer 37 also examined the combined effectiveness of sucrose with NNS for relieving procedural pain in neonates and reported that, although physiologic and behavioral changes resulted from both sucrose and nonnutritive interventions, the combined effect was the greatest. Similarly, our earlier work indicated that sucrose and pacifiers were most effective in reducing pain from single heel lance procedures in preterm neonates when compared with standard care, prone positioning, and pacifiers with water (although when compared with standard care, this intervention was also significant). 22 In contrast, Carbajal et al's findings supported the efficacy of pacifiers alone over sucrose. 38 The question of whether sucrose plus pacifiers would be efficacious and safe in reducing procedural pain if used continuously had not been addressed.
The incidence of adverse events reported in this study was very low, and all immediate adverse events resolved spontaneously without intervention. These results are similar to Gibbins et al, 23 who reported only minor side effects (eg, oxygen desaturation, choking) in 3% of the study population. The dose of sucrose administered in this study was considered to be safe in the consistent management of procedural pain during the neonatal period. The sucrose dose used (0.1 mL of 24% solution) was based on the findings of an earlier metaanalysis. 39 In studies by Stevens et al 22 and Johnston et al, 40 very small volumes of 24% sucrose (estimated at 0.01-0.02 g or 1-2 drops) significantly reduced pain in preterm infants. A recent systematic review and meta-analyses (evaluating 44 randomized control trials and including 21 in the review) 15 found that sucrose reduces procedural pain from heel lance and venipuncture in neonates, with minimal to no side effects. A sucrose dose range for reducing pain associated with procedures in neonates has been identified as 0.012 to 0.12 g (0.05-0.5 mL of 24% solution) of sucrose. There were no statistically significant differences found in any of the severity of illness scores or neurobiological risk status outcomes. The strengths of this study included central randomization and strategies used to reduce threats to internal validity. To minimize bias, trained coders were used to evaluate facial actions of the infants in this study. Contamination was minimized by controlling for the distribution of study pacifiers and sucrose. Sucrose was not readily available in the participating NICU and was provided to study patients only. Study pacifiers were not routinely used during painful procedures in this site. Infants in all study groups were exposed to other interventions that were associated with standard care in the NICU. These potential interventions were minimized by having the same research nurse interact with the staff nurses on a daily basis and by adhering to a study protocol that was acceptable to the health care professionals in the NICU. The results of this study could contribute to future meta-analyses that evaluate the consistent use of sucrose to reduce pain in infants. However, future studies would need to be undertaken using similar dosing regimes and standardized measurement of outcomes with validated infant pain measures so that data sets could be combined.
There were also a few methodological limitations to this study. The use of pacifiers in the water plus pacifier and sucrose plus pacifier groups (and not the standard care group) precluded double blinding. However, caregivers who delivered the interventions were not involved in measuring the research outcomes, and individuals who were responsible for data entry and analysis were blind to group assignment. The PIPP scores were not available on all infants for all sessions because some of the infants did not have routine blood work at each follow-up session or they were discharged home prior to the end of the 28-day data collection period. If a case deletion method of analysis were used, only those infants for whom we had completed data for all follow-up sessions could be used in the analysis. This approach would potentially introduce bias, as these infants could be systematically different from those who did not complete the 4 follow-up sessions. Therefore, to increase the precision of our results, the available-case analysis method allowed for all available PIPP scores to be evaluated in the efficacy analyses.
Further investigations of clinical, developmental, and economic effects of using repeated administrations of sucrose in both preterm (of varying gestational ages; especially those who are ,26 weeks GA) and term neonates needs to be undertaken to support the generalizability of our findings. Infants also need to be followed much further along the developmental trajectory (eg, up to 2 years of age) to adequately evaluate developmental outcomes. Also, to optimize pain relief and to understand the underlying mechanisms of sucrose and pain relief for preterm neonates, there is a need to evaluate the use of sucrose in combination with other behavioral and pharmacologic interventions for more invasive and painful procedures.
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